Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer

NCT ID: NCT01764802

Last Updated: 2018-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2017-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized phase II trial studies how well psychosexual intervention works in patients with stage I-III gynecologic or breast cancer. Psychosexual intervention may improve sexual and psychosocial function.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Efficacy for reducing the severity of sexual distress, difficulty, and dysfunction in a phase II randomized clinical trial (RCT).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (Enhanced standard care): Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding gynecologic or breast cancer treatments and sexuality, and provision of a survivorship care plan (SCP) created using OncoLink over 1 hour following baseline assessment and before 6 months.

ARM II (Psychological intervention): Patients participate in individual or group therapy over 1.5 hours weekly for 4 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.

After completion of study treatment, patients are followed up at 3, 6, and 9 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Sarcoma Ovarian Stromal Cancer Stage I Uterine Sarcoma Stage I Vaginal Cancer Stage I Vulvar Cancer Stage IA Cervical Cancer Stage IA Endometrial Carcinoma Stage IA Fallopian Tube Cancer Stage IA Ovarian Epithelial Cancer Stage IA Ovarian Germ Cell Tumor Stage IA Primary Peritoneal Cavity Cancer Stage IB Cervical Cancer Stage IB Endometrial Carcinoma Stage IB Fallopian Tube Cancer Stage IB Ovarian Epithelial Cancer Stage IB Ovarian Germ Cell Tumor Stage IB Primary Peritoneal Cavity Cancer Stage IC Fallopian Tube Cancer Stage IC Ovarian Epithelial Cancer Stage IC Ovarian Germ Cell Tumor Stage IC Primary Peritoneal Cavity Cancer Stage II Endometrial Carcinoma Stage II Gestational Trophoblastic Tumor Stage II Uterine Sarcoma Stage II Vaginal Cancer Stage II Vulvar Cancer Stage IIA Cervical Cancer Stage IIA Fallopian Tube Cancer Stage IIA Ovarian Epithelial Cancer Stage IIA Ovarian Germ Cell Tumor Stage IIA Primary Peritoneal Cavity Cancer Stage IIB Cervical Cancer Stage IIB Fallopian Tube Cancer Stage IIB Ovarian Epithelial Cancer Stage IIB Ovarian Germ Cell Tumor Stage IIB Primary Peritoneal Cavity Cancer Stage IIC Fallopian Tube Cancer Stage IIC Ovarian Epithelial Cancer Stage IIC Ovarian Germ Cell Tumor Stage IIC Primary Peritoneal Cavity Cancer Stage III Gestational Trophoblastic Tumor Stage III Uterine Sarcoma Stage III Vaginal Cancer Stage III Vulvar Cancer Stage IIIA Cervical Cancer Stage IIIA Endometrial Carcinoma Stage IIIA Fallopian Tube Cancer Stage IIIA Ovarian Epithelial Cancer Stage IIIA Ovarian Germ Cell Tumor Stage IIIA Primary Peritoneal Cavity Cancer Stage IIIB Cervical Cancer Stage IIIB Endometrial Carcinoma Stage IIIB Fallopian Tube Cancer Stage IIIB Ovarian Epithelial Cancer Stage IIIB Ovarian Germ Cell Tumor Stage IIIB Primary Peritoneal Cavity Cancer Stage IIIC Endometrial Carcinoma Stage IIIC Fallopian Tube Cancer Stage IIIC Ovarian Epithelial Cancer Stage IIIC Ovarian Germ Cell Tumor Stage IIIC Primary Peritoneal Cavity Cancer Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (enhanced standard care)

Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.

Group Type ACTIVE_COMPARATOR

behavioral, psychological or informational intervention

Intervention Type OTHER

Participate in enhanced standard care

Arm II (psychological intervention)

Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.

Group Type EXPERIMENTAL

behavioral, psychological or informational intervention

Intervention Type OTHER

Participate in psychological intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

behavioral, psychological or informational intervention

Participate in enhanced standard care

Intervention Type OTHER

behavioral, psychological or informational intervention

Participate in psychological intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stage I-III gynecologic (any site) or breast cancer
* Able to speak/read English
* Able to give informed consent

Exclusion Criteria

* Prior non-gynecologic/breast cancer diagnosis
* Refusal of any cancer treatment(s)
* Non-ambulatory
* Concurrent diagnosis of organic brain syndrome, dementia, mental retardation, or significant sensory deficit
* Major mental illness (e.g, schizophrenia, major depressive disorder)
* Current/recent (prior 12 months) pregnancy
* Residence \> 70 miles from research site
Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

Ohio State University Comprehensive Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kristen Carpenter

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kristen M. Carpenter, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Ohio State University Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

Columbus, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Black LL, Conroy K, Lustberg M, Salani R, Andersen BL, Carpenter KM. Association of sexual pain and psychological factors among gynecologic and breast cancer patients: application of components of the fear-avoidance model of chronic pain. J Behav Med. 2025 Jun;48(3):536-543. doi: 10.1007/s10865-025-00560-3. Epub 2025 Mar 13.

Reference Type DERIVED
PMID: 40082377 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2012-01341

Identifier Type: REGISTRY

Identifier Source: secondary_id

1R21CA149675-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

OSU-10077

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Couples' QOL in Metastatic Breast Cancer
NCT05636943 ACTIVE_NOT_RECRUITING NA